Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 45 - Any |
| Updated: | 4/17/2018 |
| Start Date: | January 2012 |
| End Date: | June 2020 |
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
This clinical trial is a prospective, randomized, controlled, multicenter, study. After
informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
severity, eye health, and visual acuity. Following successful screening, use of all topical
glaucoma medications will be stopped for a period of "washout" to establish a qualifying
medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over
the course of the 24 month study, and examinations will be repeated to monitor eye health. At
the 1 and 2 year follow up, those patients on ocular hypotensive medications will be
instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and
afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The
primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24
months diurnal IOP following medication washout.
informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
severity, eye health, and visual acuity. Following successful screening, use of all topical
glaucoma medications will be stopped for a period of "washout" to establish a qualifying
medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over
the course of the 24 month study, and examinations will be repeated to monitor eye health. At
the 1 and 2 year follow up, those patients on ocular hypotensive medications will be
instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and
afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The
primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24
months diurnal IOP following medication washout.
Inclusion Criteria:
- An operable age-related cataract
- A diagnosis of POAG treated with 1 to 4 hypotensive medications
- Medicated IOP ≤ 31 mmHg
- Diurnal IOP ≥ 22 mmHg and ≤ 34 mmHg
Exclusion Criteria:
- Congenital or developmental glaucoma
- Previous argon laser trabeculoplasty
- Ab-interno or ab-externo device implanted in or through Schlemm's Canal
- Use of oral hypotensive medication for glaucoma for treatment of fellow eye
We found this trial at
27
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials